Seizure
`
`1992;l
`
`(Suppl.
`
`A): 1
`
`Introduction
`
`readers and our
`to you, both our regular
`of presenting
`the opportunity
`that we have
`I am pleased
`new readers attending
`the epilepsy conference
`in Glasgow,
`the abstracts of the Epilepsy Europe
`meeting. We have designed a programme
`that will encompass all the varied aspects of epilepsy-
`basic science, medical, psychological,
`behavioural
`and social
`topics-and
`which will
`reflect
`their
`equal
`importance,
`because a true understanding
`of epilepsy embraces
`them all. This is a Conference
`which, perhaps
`for the first time, will be attended by scientists, medical doctors, non-medical
`health
`personnel and lay people, all with an interest
`in, or personal experience of, epilepsy, and all meeting
`on the same site.
`find not only their
`they will
`discipline of the delegates
`the particular
`It is our hope that whatever
`own interests
`represented
`in the conference, but will
`learn something
`of the interests and expertise
`of others, and will be able to make
`their own personal contribution
`to the
`ideas, discussions and
`debates
`that
`the conference will generate.
`It is our particular wish that
`the conference will not only
`address and reflect
`the many startling
`changes
`that are
`taking
`place
`in the sciences related
`to
`epilepsy and in medical practice
`itself, but that
`it will also look at how these changes will affect the
`lives of people who have to cope with epilepsy and how the benefits of basic research
`in epilepsy and
`the changes
`in medical practice can be brought
`to the several million people with epilepsy who live
`within our new Europe.
`types of session. Pride of place will
`To achieve
`this aim the conference will contain several distinct
`go to the posters. All contributions
`to the conference will be in poster form
`(with sufficient
`time built
`into
`the conference
`for
`their perusal and discussion
`so that
`their
`information
`can be properly
`assimilated
`and disseminated).
`There will be formal poster discussion sessions, information-giving
`sessions (plenary sessions), discussion sessions (seminar sessions),
`‘teach-ins’
`(breakfast
`sessions),
`workshops and audio-visual
`presentations.
`The purpose of the abstracts
`is to give you a chance of deciding
`particularly
`want
`to see and those authors
`that you particularly
`want
`those sessions that you will want
`to attend.
`of this abstract
`the production
`We owe a debt of gratitude
`to Marion Merrell Dow who sponsored
`book, and
`to the workers
`from
`the Epilepsy Association
`of Scotland and
`the West of Scotland
`Epilepsy Research Group who helped
`to assemble
`the abstracts
`together.
`May
`I take
`this opportunity
`of wishing you a happy and rewarding
`stay in Glasgow and hope that
`you will experience
`something
`of the rich variety of culture, hospitality
`and language
`that can be
`found within our Islands, as well as an entertaining
`and educational
`conference.
`TIM BETTS
`Chairman,
`Programme Committee,
`
`you
`that
`on those posters
`to meet and talk with and
`
`Epilepsy Europe 1992
`
`ARGENTUM Exhibit 1106
` Argentum Pharmaceuticals LLC v. Research Corporation Technologies, Inc.
`IPR2016-00204
`
`Page 00001
`
`

`
`z
`a
`i=
`u
`0
`0
`ti
`z
`0
`I-
`90
`T x W
`
`OJ
`z
`
`0
`
`IV
`I'd
`1'1'
`1'11'
`1'1'
`1‘1'
`ItI/
`'I'1
`'I'1
`'I'1
`l-
`"'1
`Y
`‘I’1
`c!
`‘I’1
`h
`‘1’1
`’
`#I
`q
`$1 1'1'
`n
`1'1'
`1'1'
`1'1'
`A'
`1'1'
`1'1'
`1'1'
`1'1'
`1'1'
`1'1'
`rg
`'I"
`;I;1
`
`:
`
`-
`
`G
`-
`:
`
`SNIkEllW3
`
`11111111
`'1'1'1'1'1'1'1'1
`~r~l~lfl~l~l~rfI
`
`r
`
`fIvmIvAv?dsIa
`
`Page 00002
`
`

`
`HOW TO USE THE ABSTRACT BOOK
`
`The Abstract Book is divided into three sections
`Sessions / Posters
`/ Videos
`There
`is a presenters’
`index at the back of the Abstract Book
`number of the paper being presented.
`
`:
`
`INDEXING
`ABSTRACT
`All abstract numbers are preceeded by a letter as follows
`S
`- indicates a oral session
`P
`- indicates a poster session
`V
`- indicates a video session
`
`:
`
`indicating
`
`the reference
`
`ORALSESSIONNUMRERING
`Sl/l
`= The first conference session and the first presentation.
`SYl/ 1 = The first Youth Satellite oral session and presentation.
`SLl / 1 = The International
`League Against Epilepsy Session and first presentation.
`
`POSTERSESSIONNUMBERING
`P2/3 = Poster Topic Group 2 - “Miscellaneous”
`
`and Poster Number 3 in that Group.
`
`the programme
`
`I'OSTERTOPICGROUPS
`in the abstract book,
`Posters are grouped by topic
`and the poster areas in Hall 3.
`1
`- Youth
`2
`- Miscellaneous
`3
`- Basic Mechanisms of Epileptogenesis
`4
`- Mental & Associated Handicaps
`5
`- Disability & Rehabilitation
`- Women with Epilepsy
`6
`- New Anti-epileptic
`Drugs
`- Epilepsy Surgery
`- Childhood Epilepsy
`-
`Investigation
`of Epilepsy
`- Non-pharmacological
`Treatment
`- Quality of Life
`- Medical Management
`- Behaviour & Cognition
`
`s’
`9
`10
`11
`
`:;
`14
`
`VIDEOSESSIONNUMBERING
`V4 = Video number 4 in the main video programme
`
`and abstract book.
`
`Please note:
`Not all presentations
`
`have corresponding
`
`abstracts.
`
`Page 00003
`
`

`
`POSTER ABSTRACTS
`
`- New Anti-mihatic
`
`Drum
`
`W/45 DOUBLEBLINDPARALLELCOMPARlSONOFTOPIRAMATEWlTHPLACEBO
`lNPATlENTSWITHREFRACTORYPARTIALEPILEPSY
`MK
`Sharief,
`JWA
`Sander,
`PN Patsalos
`and SD Shorvon,Epilepsy
`Research
`Epilepsy,
`Gerrards
`Cross,
`Bucks,
`England
`
`Group,
`
`National
`
`Hospital-Chalfont
`
`Centre
`
`for
`
`profile
`safety
`and a good
`in animal models
`properties
`antiepileptic
`has effective
`that
`compound
`is a novel
`Topiramate
`topiramate
`400 mg or 4OOmg
`daily
`as add-on
`of oral
`evaluated
`the efficacy
`and safety
`This
`study
`oral administration.
`epilepsy.
`total
`of 25 adult
`patients
`(24 males, mean
`age + I- SD = 34.7+ 1-9.1
`years)
`A
`with
`partial
`therapy
`in patients
`included.
`They
`had at
`least 8 seixures
`in a baseline
`period
`of 8 weeks with
`a longest
`epilepsy
`were
`retiactory
`partial
`3 weeks.
`Patients
`were
`randomized
`either
`to placebo
`or
`topiramate,
`which
`were
`titrated
`of
`less
`than
`seizure-free
`interval
`up
`to
`the assigned
`dose,
`using
`a BD
`regimen,
`in addition
`to
`the patients’
`existing
`therapy
`of one or
`weekly
`increments
`on
`Dose
`titration
`was
`followed
`by 8 weeks
`stabilisation
`period
`the same
`regimen.
`Of
`the 20 patients
`who
`antiepileptics.
`completed
`the study,
`9 were
`treated
`with
`topiramate
`and
`showed
`a significant
`reduction
`in median
`seizure
`successfully
`per 2-month
`period
`(p>O.OS).
`There
`was a median
`decrease
`in partial
`seixums
`of 4096 on
`the active
`drug
`(p<O.Ol),
`frequency
`the 9 patients
`experienceing
`~70%
`reduction
`and another
`2 experiencing
`60-7096
`reduction.
`Mean
`seixure-free
`with
`2 of
`interval
`in 4 patients
`increased
`from
`6+1-0.5
`days
`to 47+/-10
`days
`after
`the
`initiation
`of
`topiramate
`therapy.
`Mild weight
`loss was observed
`in 3 patients,
`2 patients
`developed
`mood
`changes,
`and mild
`tremor
`was detected
`in one patient.
`Adjuvant
`topiramate
`may
`improve
`the control
`of parial
`seizures
`in patients
`with
`refractory
`epilepsy.
`Long-term
`required
`to evaluate
`the safety
`and efficacy
`of oral
`topiramate
`these patients.
`
`after
`
`with
`
`by
`two
`
`studies
`
`are
`
`in
`
`W/46 APlLOTSTUDYOFTHEEFFICACYANDTOLERABILlTYOFL059
`INPATIEIVI'SWITHREFRACTORYEPILEPSY
`P Sigh.
`MK
`Shariec
`JWA
`Sander,
`PN Patsalos,
`and SD Shorvon,
`Centre
`for Epilepsy,
`Gerrards
`Cross,
`Bucks,
`England
`
`Epilepsy
`
`Research
`
`Group,
`
`The National
`
`Hospital-Chalfont
`
`in a
`activity
`antiepileptic
`has a potent
`of piracetam,
`(S) enantiomer
`is the
`LO59. which
`drug
`antiepileptic
`A new potential
`no sign of d iminished
`with
`wide
`range
`of animal models
`blind,
`add-on,
`This
`single
`chronic
`administration.
`activity
`after
`Seventeen
`adult male
`epilepsy.
`in patients
`with
`retiactory
`the efficacy
`and
`tolerability
`of Lo59
`rising
`dose pilot
`study
`evaluated
`antiepileptic
`drugs,
`were
`three
`to
`who were
`receiving
`up
`patients
`(mean
`age = I- SD=42.4+/-9.8
`years)
`with
`refractory
`epilepsy
`by a 16-week
`active
`included
`in
`this
`study.
`The
`study
`began with
`a 4-week
`observation
`period
`on placebo
`followed
`up
`treatment
`period,
`which
`started
`with
`500 mglday
`of LO59 and
`subsequent
`increments
`of SOOmglday
`every
`4 weeks
`or
`total
`dose of 2ooO mglday.
`Three
`patients
`withdrew
`due
`to
`increase
`in seizures
`or
`intolerable
`side effects
`(diplopia
`in
`behavioural
`changes).
`Of
`the 14 patients
`who
`successfully
`completed
`the study,
`three
`experienced
`80-10896
`reduction
`seizures,
`achieved
`SO-7955
`reduction,
`and another
`two patients
`achieved
`30-4996
`reduction.
`Median
`seizure
`frequency
`two
`similar with
`1OOOmg and 2000mg
`daily.
`Relevant
`side effect
`included
`drowsiness
`(5 patients),
`cognitive
`month
`was
`relatively
`mood
`changes
`(3 patients),
`and headache
`(2 patients).
`Four
`patients
`are still on
`the drug
`after
`13 months
`of
`treatment
`with
`(2000mg
`daily)
`with
`no
`loss efticacy.
`These
`results
`suggest
`that
`oral LO59 may
`have
`antiepileptic
`activity
`in patients
`intractable
`epilepsy.
`Double-blind,
`controlled,
`and
`long-term
`studies
`are
`required
`to evaluate
`the efficacy
`and
`safety
`of
`drug.
`
`per
`or
`
`this
`
`to a
`
`P7/47 LONGTERMTREATMENTWITHTOPIRAMATEINREFRACTORYPARTIALEPILEPSY
`ATWO-YEARFOLLOW-UPSTUDY
`Research
`hi K Sharief,
`J WA
`Sander
`and SD Shorvon,
`Epilepsy
`National
`Hospital-Chalfont
`Centre
`for Epilepsy,
`Gerrards
`Cross
`
`Group,
`Bucks,
`
`Institute
`England
`
`of Neurology
`
`and The
`
`that
`
`therefore,
`and,
`in animals
`seixure
`electroshock
`the maximal
`in
`spread
`seizure
`blocks
`compound
`is a novel
`Topiramate
`as add-on
`therapy
`topiramate
`or oral
`and efticacy
`the safety
`evaluated
`This
`open
`study
`may
`be effective
`in partial
`epilepsy.
`treated
`with
`who were
`9.2 years)
`mean
`age 34.9 +I-
`(17 males,
`total
`of 18 patients
`with
`refractory
`partial
`epilepsy.
`A
`with
`a median
`per month,
`double
`blind
`trial were
`included.
`All had at
`least 4 seizures
`placebo
`or
`topiramate
`in a previous
`seizure-free
`interval
`of 6 days.
`On study
`entry
`patients
`were
`titrated
`up
`to
`theii maximum
`effective
`or maximum
`tolerated
`dose of
`topiramate
`without
`alteration
`of
`theii
`concomitant
`one or
`two antiepileptics.
`Thirteen
`patients
`(78%)
`responded
`topiramate
`and are still
`on a mean
`dose of SOOmglday
`(administered
`on a BD
`regimen).
`Five
`patients
`withdrew
`due
`to
`of
`therapeutic
`effect
`or
`increase
`in seizures
`(3 patients),
`mood
`changes
`(1 patient),
`or detection
`of a renal
`calculus
`(1
`patient).
`Median
`seixure
`days were
`significantly
`reduced
`with
`topiramate
`(pcO.01).
`Four
`patients
`achieved
`~70%
`reduction
`seizures,
`and 6 patients
`experienced
`SO-7096
`reduction.
`There
`was no sigr.d.Bcant
`loss of efBcacy
`with
`contimred
`treatment.
`effects,
`which
`were
`usually
`mild
`reversible,
`included
`diarrhoea
`(3 patients),
`dirxinesslataxia
`(4 patients).
`and
`cognitive
`and
`mood
`changes
`(3 patients).
`No
`long-term
`side e&cts
`have
`been detected.
`Topiramate
`seems
`to be a valuable
`new drug
`for
`the
`treatment
`of refractory
`partial
`epilepsy.
`Longer
`tiztllow-up
`studies
`are
`required
`thorougb.ly
`evaluate
`the efficacy
`and
`safety
`of
`this
`drug
`in patients
`with
`epilepsy.
`
`to
`lack
`
`of
`Side
`or
`
`to
`
`Page 00004
`
`

`
`V033
`
`S37/5
`
`V031,
`
`V032,
`
`P14/04
`
`E, P7/04,
`P13/04
`
`S21/4,
`
`P11/04,
`
`R, S36/2
`
`N, P14/01
`Aachi
`N, PlO/Ol
`Ada&i
`U, P13/01
`Aguglia
`P10102
`G, P7/01,
`Alarcon
`A, PS/Ol,
`P14/02
`Aldenkamp
`W. S43/4
`Alpha&s
`J, P7/02,
`P9/01
`Alving
`E F, V028,
`American
`Amos
`P, P4/01
`Anderson
`E, P8lOl
`Andronikashvili
`G, P10103
`Anhut
`H, P7/03
`Antadze
`Z, P13/02
`Appleton
`R, S1114
`Arvie
`S, P12123
`Ashby
`B, P12/01
`Aspinall
`P, PlllOl
`Austin
`J, S27/2
`E F, VOOS
`Australia/Victoria
`Australian
`N E A, VO09
`Babu R, P14/03
`S23/3
`Baker
`G, P12/02,
`M, P3/01,
`Baldy-Mouiinier
`A, S7/ 3
`Beaumanoir
`M & J. S4Oll
`Beaussert
`Becu M, P11102
`Bedlington
`N, S113
`Beech
`L, P12/03,
`P12/04
`Beghi
`E. S30/4
`Bekes
`J, P11103
`Ben-Menachem
`Beran
`R, P13/03,
`Bergin
`P, P10104
`P4/03
`Bemey
`T, P4/02,
`S17/1
`Besag
`F, P13/05,
`P6/02,
`Betts
`T, P6/01,
`P13/06
`Betts
`T, P12/06,
`S21/3,
`S25/3
`Betts
`T, S5/1,
`V017,
`V018
`Betts
`T, VOll,
`Bibiieishvili
`S, P 10105
`Binnie
`C, S38/4
`Birbaumer
`N, S25/4
`Bisgard
`C, P4/04
`Bloome-Dorme
`Boden
`S, S12/3
`Boidein
`F, P14/05
`Boon D, P13/07
`Brantner
`S, P7/05
`Bray
`P, P12/06
`Bressi
`C, P12107
`British
`E A, VOO4. VO06, VOlO,
`Brodie M, P3/02,
`P7lO6,
`P12108
`Brodie M, S21/1,
`S37/1
`Brodtkorb
`E, P10106
`Broer M, P 12109
`Brown
`R, PllOl
`Brown
`S, S19/1,
`Bruton
`C, S41/3
`Buchanan
`N, P7/07,
`Bullmore
`E, P 10107
`Burman
`H, S10/2
`Burns
`R, S12/5
`Caimie
`V, P6/03,
`Caliaghan
`N, P7/08
`
`V024,
`
`V029
`
`S26/1
`
`P13/08
`
`S1104. S44/3
`
`INDEX
`
`S36l7
`P 12110
`
`M, S32/1,
`R, P9/02,
`E, P14/06
`S, P11105
`A, PlZlll
`D, S8/3
`J, P5/02
`A, P7/59.
`K, P11106,
`B, PlZI12,
`J, P13/10
`H, P13/11
`S, P8/02
`T, P10108
`
`Canevini
`Canger
`Castelh
`Cerino
`Cemibori
`Chadwick
`Chaplin
`Chapman
`Chapman
`Chappell
`Chataway
`Chaudhry
`Chkhenkeli
`Chkhikvishvili
`Clark
`J, P14/07
`Cocito
`L, P7/09,
`Collens
`J. P5/03,
`Cook M. P10109,
`Cooke
`E. P7/11
`Coppola
`G, P7/12
`Corbett
`J, S34ll
`Corcoran
`R, P 14109
`Comaggia
`C, S30/2
`Covanis
`A, P9/03
`Crawford
`P. P7/13,
`Cregeen
`S. P11107.
`Croucher
`M. P3/03
`cull
`c, P11109
`Dahl
`J, S25/2
`Dam M, Slll2
`Davidson
`D, P3/04,
`De Castro
`Siiveira,
`De Deyn
`P, P7/15
`De Maria
`G, P2lOl
`De Puit M, PllllO
`Deb S, S26/2
`Devetag
`F, P9/04
`Dhir M, P9/05
`Donaghy
`L, P5/05,
`Dowds
`C, PO7/02,
`Dravet
`C, S42/1
`Duchting-Roth
`Duffy
`N, S35/1
`Dulac
`0, S2112
`SllI5,
`Duncan
`J, SL113.
`Duncan
`R, P10/12,P10149,
`Duncan
`S, P6/04,
`P10113,
`Durmuller
`N, P3/05
`Elder
`S, P 1102
`Elian M. P9/06
`Emre M, S6/4
`Engelsen
`B, Pl3/12
`Engelskjon
`T, P7/ 16
`Espie C, P4/05,
`S36/6
`Farrell
`K, P10115,
`P10116,
`Faught
`E, P7/17
`Fenton
`G, P4lO6
`Fenwick
`P; P10117.
`Feucht
`M. P10118
`Ffytche
`D. P8/03
`Fidler
`C, P4/07
`S16/3
`Fiebig
`U, P12/47,
`Fiih
`E, VOOZ, VOO7. V012
`Flink
`R, P10119,
`PlOl20
`
`S6/2,
`S39/4
`P13/09,
`
`S22/1
`
`S46/1
`
`P7/10
`P5/04
`P10110,
`
`PlOIll,
`
`P14/08
`
`P7/14
`P11108
`
`P12113
`P12114
`
`S1214
`VO08
`
`A, Plllll
`
`S13/3
`S38/2
`P10114
`
`S41/2
`
`S25/1
`
`P12115
`P12/15
`P8/04.
`
`P14/12
`
`S43/3
`
`P9/09
`
`P14/15
`
`P12118
`
`M, S39/3
`Forsberg
`M, Pllll2
`Foulon
`A, P14/ 10
`Fowler
`G, S38/ 1
`Franck
`E, P7/ 18
`Franzoni
`Free
`S, PlOl21
`Frequin
`S. PlOl22
`Friis M, P7/19,
`S4511
`Fuggle
`K, P11113,
`P11114
`Galimberti
`C, P14/11,
`P13/13
`Gardiir
`R, S3111
`Garofalo
`P, P6/05,
`Geladze
`T. P6/065,
`Gillham
`R, P7/20,
`Giudice
`E, P7/21
`Goldstein
`L, P8/05,
`Gram
`L, S13/2
`Gratadou
`J, P14/13
`Gray
`J. P7/22
`Groselj
`J, P12116
`Guerreiro
`C, P9/08,
`Gupta
`R, P9llO
`Gutter
`T, P10123
`Hanscomb
`A, V023
`Harms
`A, P12117
`Hamor
`M, P14/14,
`Harvey
`J. P5/06
`Hasae D, V013
`Heathcote
`D, Pll/lS
`Heaton
`M, P6/07,
`Hendriks
`M, P14/16
`Hevey
`D, VO30
`Hill D, P7/23
`S. P8/06
`Hiibayashi
`K. P13/14
`Hiital
`V015
`E, P13/15,
`Hirsch
`Hiiasniemi
`A. P4/08
`Hisano
`T. P10124,
`P14117
`Hoare
`P, S23/2,
`S2713
`Hoffmann
`D, P12/19,
`Holmes
`0, P3/06
`Hughes
`M, P9/11,
`Hunt
`A, P9/12
`Huyton
`M, P13/16
`International
`LA
`Ioseliani
`T, P3107
`Jackson
`G, PlOI25.
`Jacoby
`A,
`PlZI22,
`Jadresic
`D, P2103
`Jam
`P, P13/19
`JaBon
`P, Sl/Ol
`Jambaque
`I, S4113
`Japaridze
`G. P13/28
`Jeffries
`J. S14/3
`Jenkins
`L, P14118
`Jibladze
`M, P10127
`Jones R, S22/4
`Jongsma
`M, V016
`Kakiasltvili
`R, P10128
`Kalviainen
`R. P7/24,
`Kantardzic
`D L, P6/08
`Kasteleijn-Nolat,
`P12124,
`Keating
`J, P13/21
`Kempff
`M, P5/07
`
`PlZI20,
`
`Pl2/21
`
`S1014
`
`E, P13/17
`
`P10126
`P13/18
`
`P7/25
`
`S39/2
`
`Page 00005
`
`

`
`INDEX
`
`P13/31
`
`P7/33,
`
`P9/17
`
`K. SlOl 1
`Nakken
`New Zealand
`E A, VO03
`Nicolaishvili
`R, P13/30
`Niirova
`A. P3/15
`Niison
`B, P10135
`Niison
`L, P12/34
`Nissila M, P10136
`Nordli
`D, Pl3/ 10
`O’Connor
`Bird M. S16/2
`O’Driscoll
`K, P14/20
`O’Hare
`P, PSllO
`G’Rourke
`M. P4/09
`Okujava
`N. P10137,
`Gmtzigt
`J, P6111
`Oosterhuis
`A, P11117
`Ostgard
`R, S9/4
`0we.n
`B, SYlll
`Owen
`L, P7/32,
`Oxley
`J, S16/1
`Paci M. P9/18
`Palha
`P. P12/35
`Panagopoulos
`G. P10138
`Parkingson
`G, P9/19
`Parsonage
`M, S40/3
`Passingham
`C, Pa/11
`Patterson
`W, P10139
`Pearson
`J, S1212, V025
`Pedley
`T. SL116
`Pedroli
`L. Pll/lB
`Perruca
`A. S1113
`Petridou
`M, P14/21
`Piaazini
`A, P12136
`Pickles
`CD. P14/22
`Pinard
`E, S44/4
`Piscaglia
`M, P4/10
`Prier
`S, P10140
`Rajna
`P. P11119,
`Ravnik
`I, P12l37,
`Regesta
`G, P12139
`Reiter
`J S32/1
`Reker M, P11120
`Remmel
`R, P7/34
`SlS/l
`P12140,
`Renier W, P6/12,
`Rentmeester
`T, P7/35,
`P7/36,
`Reynolds
`E, SL115
`Richens
`A, P7/37,
`Riekkinen
`P, S1117
`Rig
`H, P7/39.
`P7/40
`Riiner
`M. P7/41
`Roberts
`R, PSI12
`Rodger
`C, P7/42
`Rugland
`A, P14/24
`Ryan M, P1104
`Sabers
`A. P13/34
`Sandvig
`I, P10141
`Santiago
`M, P4/11
`Sasso E, P7/43
`Scambler
`G, S513
`P11121
`Schier
`E, P9/20,
`Schlumberger
`E. P9/21
`Schmidt
`D, S8/1,
`S13/1
`Schmitz
`B, P10142,
`PI3135
`Schwager
`H. P9/22.
`S29/1
`Scottish
`E A, V027
`
`P14/23
`P13/32,
`
`P14/38
`
`P13133
`
`P7/38,
`
`S37/4
`
`P7145,
`
`P7146.
`
`P7/47
`
`P7/51,
`
`P13/37
`
`S311, S30/3
`
`P13/39
`
`P9/25,
`
`S42/3
`
`P10143.
`
`Plot44
`
`P13/41
`
`.943/l
`P13/40,
`
`R, P13/36
`-viii
`A, P3/16
`Shandra
`M, P7/44.
`sharief
`I. P12141
`Shim&on
`S, SL114
`Shorvon
`Sii
`G. P7/48,
`P7/49
`skaare
`s, S29l3
`Skecn
`0. P3/17
`Smith D. P7150.
`Smith
`S. S6/3
`Soderfeldt
`B. P14/25
`P12142,
`Sormen
`A, PllI22,
`v021,
`vO26
`sonnen
`A, VOOl,
`P12143
`Speahio
`L, P6/13,
`Qedmann
`E P3/18,
`S14/2
`Staugenberg
`E, P9123
`Stewart
`A, P12144
`Stewart
`J, P13/38,
`Stone T, S44/1
`Stores G. P9l24.
`Straub
`H. V014
`Stumiolo
`rd. P14/26
`Sundqvist
`A, PO2/05
`Suurmeijer
`T, S23/4
`Sveinbjomsdottir
`S, P7/52,
`Symes
`R. S9/1,
`S36/5
`Tallis
`R. S18/ 1
`Tanganelli
`P, P10145
`Tatishvili
`N. P10146
`Thomas
`P. S42/2,
`VO19
`Thompson
`P. P12145.
`Timmings
`P. P7/53,
`Tirelli
`F. P14/27
`To&e
`0. PO2106
`Tomiak
`W, S29/2
`Tomson
`T, P13/42
`Trimble
`M. S1116
`Trottier
`S, P3/19
`Uldall
`P. S7/4
`Ulku
`D. S39/1
`P11123
`Upton
`D, P8/13.
`s39/2,
`usiskin
`s, P11124,
`Van Der Kuip,
`S29/5
`Van Engelen
`B, P7/54.
`Vecchio
`F, P2107
`Velasco
`P. P8/ 14
`Vermeulen
`J, P14/28
`Volpato
`D, P14/29
`Voskuyl
`R, P7/55
`Walker
`R. P13/43
`Wallace
`S. P9/28,
`Wannag
`E, P10147
`Watt
`A, P12146
`Weaver
`D, P7/56
`West
`P. S27/4
`White
`H, P7/57
`Whitehouse
`W. P3/20
`Wiser
`H, P10148,
`P13/44.
`Wijsman
`D, P13/45
`Wober
`C, P13/46
`wolf
`P, s26/3
`Yuen
`4
`P7/58
`Zaiwalla
`Z, P9/30
`Zhang W. P6/14
`
`SLl/l
`
`P9/26,
`
`P9/27
`
`P9/29
`
`+%21/S
`
`Kendrick
`Keranen
`Khandwalla
`Khrestchatrsky
`Klee M, S14/4
`Klitgaard
`H, P3/08.
`Kochen
`S, P10129,
`Komender
`J, P12/27
`Kostopoulos
`G. S44/2
`Kramer
`L. S8/2
`Kratimenos
`G, P8/07,
`Kubova
`H, P3/09
`Kumlein
`E, P8/08
`Kutzer
`M, P9/ 13
`Kvirkvelia
`N, P13/24
`Laan
`L. P13/25
`Laegreid
`L, P6/09
`s, P6/10.
`tiMOIl
`Lantz
`G, P10131
`Leenders
`K. S38/3
`Lempert
`T, P7/26
`Leober
`J, S30/ 1
`Leppik
`1. s37/3
`Leuf G, P10132
`V, S4512
`Lieb-Juckstock
`Lmdbom
`U, P3/ 10
`Liidrea
`A,
`P13/26
`Livingston
`J, S42/4
`Loeber
`J, S117
`SY114
`Logan
`E, PlJO3,
`Lomashvili
`N, Pl2/28
`Loney
`G, V022
`Louvel
`J, S22/2
`Loyning
`T, S1013
`Macdonald
`D, SlZll,
`Macdonald
`R, Sllll
`Majkowski
`J. P13/27
`Malafosse
`A, P3/11
`Malmgren
`K. P10133
`Manford
`M. P13/28
`Mansur
`G, P12129
`Mares
`P, P3/12
`Marescaux
`C, P3113
`Marston
`D, P14/19
`Martins
`da Siiva A, P11116
`McKee
`P, P7/27,
`P13/29
`McKinlay
`I, S3611
`McLii
`W, S16/4
`Medagoda
`A S, PSI08
`Meierkord
`H, P10134
`Meinardi
`H, S112
`Meldrum
`B. S6/ 1
`Menegati
`B, P7/28,
`Mengel
`H, P7/29
`Mesdjian
`E, PO2/04
`Meyer
`D, P7/30
`Meyer
`J, PS/O9
`Mikkelsen
`M, P7/31
`Millan M. P3/ 14
`Moerland
`M. S29/4
`Moretti
`I, P9/16,
`P12132,
`Morris
`P, SY113
`Muller-Holve
`W, St516
`Murari
`J, P12/33
`
`P12/26
`
`A, P12125,
`T. P13/22
`Y, S24ll
`hi, S22/3
`
`S44/3
`P13/23
`
`P10130
`
`P8/09
`
`S20/ 1
`
`P9/14,
`
`P9/15
`
`P12/31,
`
`P12/30
`
`Page 00006